4//SEC Filing
Heyman Richard A. 4
Accession 0001584759-26-000004
CIK 0001672619other
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 5:11 PM ET
Size
10.2 KB
Accession
0001584759-26-000004
Insider Transaction Report
Form 4
Heyman Richard A.
Director
Transactions
- Sale
Common Stock
[F1][F2]2026-01-08$25.00/sh−1,620$40,500→ 25,545 total(indirect: See footnote) - Sale
Common Stock
[F3][F4][F5]2026-01-08$25.04/sh−8,015$200,656→ 29,392 total(indirect: See footnote) - Sale
Common Stock
[F3][F6][F5]2026-01-09$25.00/sh−4,285$107,125→ 25,107 total(indirect: See footnote)
Holdings
- 123,673
Common Stock
Footnotes (6)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by RAHD Capital LLC, for which the Reporting Person serves as a managing member.
- [F2]The shares are held of record by RAHD Capital LLC.
- [F3]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").
- [F4]This transaction was executed in multiple trades at prices ranging from $25.00 to $25.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F5]The shares are held of record by the Heyman Daigle Trust.
- [F6]This transaction was executed in multiple trades at prices ranging from $25.00 to $25.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Signature
/s/ Ben Hohl, by power of attorney|2026-01-12
Documents
Issuer
Enliven Therapeutics, Inc.
CIK 0001672619
Entity typeother
Related Parties
1- filerCIK 0001584759
Filing Metadata
- Form type
- 4
- Filed
- Jan 11, 7:00 PM ET
- Accepted
- Jan 12, 5:11 PM ET
- Size
- 10.2 KB